Kopran Ltd - KOPRAN Share Price

Sector: Pharmaceuticals | ISIN: INE082A01010
₹ 257.05 (-3.46%) icon19 Apr, 2024, 12:00:00 AM

Kopran Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 4/19/2024 12:00:00 AM

    ₹ 257.05 -9.20 -3.46
  • Open
  • ₹ 262
  • Prev. Close
  • ₹ 266.25
  • Turnover(Lac.)
  • ₹ 711
  • Day's High
  • ₹ 262
  • Day's Low
  • ₹ 255
  • 52 Week's High
  • ₹ 292.3
  • 52 Week's Low
  • ₹ 140
  • Book Value
  • ₹ 86.06
  • Face Value
  • ₹ 10
  • Mkt Cap (₹ Cr.)
  • 1,239.25
  • P/E
  • 49.98
  • EPS
  • 5.15
  • Divi. Yield
  • 1.17

Kopran Ltd Corporate Actions

23 Jan , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

23 Jan , 2024

12:00 AM

26 Oct , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

26 Oct , 2023

12:00 AM

17 Aug , 2023

12:00 AM

AGM

Announcement date: 17 Aug , 2023

View Details

25 May , 2023

12:00 AM

Dividend

Dividend amount: 3
Announcement date: 25 May , 2023

View Details

31 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

31 Jul , 2023

12:00 AM

16 May , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

17 Aug , 2023

12:00 AM

BookCloser

View Details

No Record Found


Kopran Ltd News and Update

No Record Found

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Kopran Ltd SHAREHOLDING SNAPSHOT
20 April , 2024 | 07:53 AM

PROMOTER - TOTAL44.49%

Indian: 44.49%

Foreign: 0%

NON-PROMOTER - TOTAL 55.51%

Institutions: 2.04%

Non-Institutions: 53.47%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

Kopran Ltd FINANCIALS

Kopran Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Kopran Ltd

  • Surendra Somani
  • Executive Vice Chairman
  • Sunil Sodhani
  • Company Sec. & Compli. Officer
  • Siddhan Subramanian
  • Independent Director
  • Sunita Banerji
  • Independent Director
  • Mamta Biyani
  • Independent Director
  • Narayan Atal
  • Independent Director
  • Susheel Somani
  • Chairman (Non-Executive)
  • Adarsh Somani
  • Non Executive Director
  • Varun Somani
  • Non Executive Director

Summary

Kopran Ltd., incorporated on April 26, 1958, was promoted by the Somani group and is controlled by Parijat Enterprises. The company came out with a public issue at a premium, in Nov.92, to finance its backward integration project to produce drug intermediates for semi-synthetic drugs, and also to expand its antibiotic facility.Kopran manufactures pharmaceutical finished dosage forms and bulk drugs and distributes electronic equipment. It manufactures semi-synthetic penicillin and is among the worlds highest producers in amoxycillin. Kopran also makes penicillin-G acylase, an enzyme made through fermentation. It has technical collaborations with Gesellschaft Fur Biotechnologische, Germany; Yuhan Corporation, South Korea; Ciba Corning Diagnostic, US; and Adac Laboratories, US.Koprans bulk drug plant has been approved by the US FDA and the UK regulatory authorities. In 1995, the company was awarded the Quality Excellence award by the Indian Drug Manufacturers Association. Koprans high growth rate in exports has been recognised by a number of awards from CHEMEXCIL and the Ministry of Commerce.The company launched new products like AZ-1 Caps, Klodip Tabs, Moclox Kid Tabs, Amyn Kid Tabs, Tini-NF, Amyn Caps and Amyn Dry Syrup. Kopran entered into a joint venture with M/s Industrial Promotion Services Ltd to take over a running unit viz Kampala Pharmaceuticals Industries Ltd in Uganda.The company has been ranked as amongst the top few fastest growing companies in India(ORG Marg-June... Read More


Reports by Kopran Ltd


Reports by Kopran Ltd

Company FAQ

No Record Found